Theranova 400 透析器扩展血液透析疗效与安全性的随机对照试验
该随机对照试验纳入172例维持性血液透析患者,比较中截留膜透析器(Theranova 400)与高通量透析器(Elisio-17H)治疗24周的效果。主要安全终点为治疗24周后透析前血清白蛋白水平,主要疗效终点为治疗24周时游离λ轻链的下降率。结果显示Theranova 400组游离λ轻链下降率显著更高(24周:33% vs 17%,P<0.001),且透析前血清白蛋白水平非劣效。
要点
- Theranova 400组24周游离λ轻链下降率33%,显著高于高通量透析器的17%。
- 两组24周透析前血清白蛋白水平相似(4 g/dl vs 4.1 g/dl),满足非劣效。
- Theranova 400对补体因子D、游离κ轻链、TNFα和β2-微球蛋白的清除显著更优。
核心结论
- Theranova 400透析器较大中分子清除优于同等大小高通量透析器,且维持血清白蛋白水平。
研究设计与样本
- 多中心、前瞻性、随机、对照、开放标签、平行研究,纳入172例临床稳定的维持性血液透析患者,随机分配至Theranova 400组或Elisio-17H组各86例,治疗24周。
主要发现
- 游离λ轻链下降率在4周(39% vs 20%)和24周(33% vs 17%)均显著高于对照组(均P<0.001)。
- 4周和24周时补体因子D、游离κ轻链、TNFα和β2-微球蛋白下降率显著更大(均P<0.001),IL-6无显著差异。
- 24周透析前血清白蛋白水平两组相似(Theranova 400组4 g/dl,Elisio-17H组4.1 g/dl),符合非劣效。
关键数值与推荐
- 主要安全终点:治疗24周后透析前血清白蛋白水平。
- 主要疗效终点:治疗24周时游离λ轻链下降率。
临床怎么用
- 对于需要加强较大中分子清除的维持性血液透析患者,可考虑使用Theranova 400透析器。
局限性
- 每组86例中仅65例完成试验,脱落率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Expanded hemodialysis therapy enabled by medium cut-off membranes may promote greater clearance of larger middle molecules that comprise putative uremic solutes than conventional high-flux dialysis. This randomized trial evaluated the efficacy and safety of hemodialysis treatment with a medium cut-off dialyzer. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Clinically stable patients on maintenance hemodialysis were randomized to receive dialysis with either a medium cut-off dialyzer (Theranova 400) or a high-flux dialyzer (Elisio-17H) over 24 weeks of treatment. The primary safety end point was the predialysis serum albumin level after 24 weeks of treatment. The primary efficacy end point was the reduction ratio of free λ light chains at 24 weeks of treatment. RESULTS: Among 172 patients on maintenance hemodialysis, mean age was 59±13 years, 61% were men, 40% were Black, and mean dialysis vintage was 5±4 years. Of the 86 patients randomized to each dialyzer, 65 completed the trial in each group. The reduction ratio for the removal of free λ light chains was significantly higher in the Theranova 400 group compared with the Elisio-17H group after 4 weeks (39% versus 20%) and 24 weeks (33% versus 17%; both P<0.001). Among secondary end points, the Theranova 400 group demonstrated significantly larger reduction ratios at 4 and 24 weeks for complement factor D, free κ light chains, TNFα, and β2-microglobulin (P<0.001 for all), but not for IL-6. Predialysis serum albumin levels were similar between groups after 24 weeks (4 g/dl with the Theranova 400 and 4.1 g/dl with the Elisio-17H), consistent with noninferiority of the Theranova 400 dialyzer in maintaining predialysis serum albumin levels after 24 weeks of treatment. CONCLUSIONS: Hemodialysis therapy with the Theranova 400 dialyzer provides superior removal of larger middle molecules, as exemplified by free λ light chains, compared with a similar size high-flux dialyzer, while maintaining serum albumin level. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Multi-Center, Prospective, Randomized, Controlled, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of the Theranova 400 Dialyzer in End Stage Renal Disease (ESRD) Patients, NCT03257410.
引用
- Weiner DE, Falzon L, Skoufos L, et al. Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2020. PMID: 32843372. doi:10.2215/CJN.01210120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。